Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Centene Corp filings on SEC EDGAR ↗
Centene Corporation reported third quarter 2026 financial results, including total revenues of $50.6 billion and a GAAP diluted loss per share of $(0.14). The company increased its full-year 2026 adjusted diluted EPS guidance to greater than $5.20, citing solid fundamentals and a faster-than-anticipated recovery in its earnings trajectory.
Term
Q3 2026
“Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated. We are pleased with the progress our teams have made in delivering increased margin to power our mission of transforming the health of the communities we serve, one person at a time. We remain focused on a strong finish to 2026 and building on this progress in 2027.”
Centene $569M Debt Financing with The Bank of New York Mellon Trust Company, N.A.
Centene Corporation has issued a notice to redeem the remaining $568.664 million aggregate principal amount of its 4.25% Senior Notes due 2027. The redemption is scheduled for October 23, 2026, at a price of 100% of the principal plus accrued interest, after which no 2027 Notes will remain outstanding.
Centene Corporation is participating in the Deutsche Bank 2026 Healthcare Summit on September 16, 2026. During the event, management will discuss business results and reaffirm its full-year 2026 guidance, including GAAP diluted EPS of greater than $3.11 and adjusted diluted EPS of greater than $4.80.